CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
CYTOKINETICS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Product Revenue [Member] | $25.33M | $4.79M | – | – | $0 | $0 | – | – | – | – | – | – | 88.5% | – |
| Collaboration Revenues [Member] | $3.29M | $2.64M | $2.76M | $1.94M | $2.42M | $1.58M | $1.93M | $463.00K | $249.00K | – | – | – | 11.5% | +36.2% |
| License and Milestone Revenues [Member] | $0 | $11.93M | $15.00M | $0 | $64.35M | $0 | $15.00M | $0 | $0 | – | – | – | 0.0% | -100.0% |
| Research and Development Revenues [Member] | – | – | – | – | – | – | – | $463.00K | $249.00K | $835.00K | $672.00K | $378.00K | – | – |
| Milestone Revenues [Member] | – | – | – | – | – | – | – | $0 | $0 | $0 | $1.00M | $0 | – | – |
| Realization of Revenue Participation Right Purchase Agreement [Member] | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Cytokinetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.